- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations Investing
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Franchise and Hospitality
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Coronavirus
- Crisis Practice
- Environmental Agenda
- Focus on Women's Health
- Special Purpose Acquisition Companies (SPACs)
- The New Administration: Enforcement and Legislative Impact
- Careers
- News & Insights
- About
- Languages
Jeffrey S. Bucholtz
Insight 33 results
Article · Source: Chamber Litigation Blog
October 7, 2021
Top False Claims Act Developments
Article · Source: Chamber Litigation Blog
July 29, 2021
Top False Claims Act Developments
Article · Source: U.S. Chamber Litigation Center
July 29, 2021
Top False Claims Act Developments
Article · Source: Chamber Litigation Blog
May 25, 2021
Stats Without Facts: Another Court Rejects Data Mining Qui Tam Strategy
Client Alert
July 30, 2020
Trump Administration Continues to Promote Drug Importation as a Way to Lower the Cost of Prescription Drugs
Article · Source: Chamber Litigation Blog
June 10, 2020
The Nuisance of Nuisance Litigation
Client Alert
April 28, 2020
Constitutional Limitations On Emergency Authority
Client Alert
April 9, 2020
False Claims Act Considerations Related to the CARES Act's Small Business Administration Loan Program
Article · Source: Law360
March 19, 2020
Ruling In HHS Case May Mean More Drug Trial Reporting
Client Alert
Article · Source: Washington Legal Foundation
December 13, 2019
Taking the Granston Memo to the Next Level: Early and Close Coordination with Agencies on Qui Tam Actions